Scott T. Rottinghaus, M.D., has been appointed senior vice president and chief medical officer of Enanta Pharmaceuticals, a clinical-stage biotechnology company focused on developing novel, small molecule drugs for viral infections and liver diseases. The appointment is effective as of today, August 8, 2022.
Dr. Rottinghaus will oversee the development, regulatory, clinical, and medical operations in support of Enanta’s pipeline because she has more than 20 years of experience in drug development across a wide range of therapeutic areas.
Dr. Rottinghaus has more than 20 years of clinical experience in drug development and has specialised knowledge in a number of therapeutic fields, including dermatology, rheumatology, infectious diseases, haematology, nephrology, and rare diseases.
Dr. Rottinghaus served as vice president and head of clinical development for haematology and nephrology at Alexion, a division of AstraZeneca Rare Disease, before joining Enanta. While there, he oversaw the clinical development of several products, including ravulizumab, a humanised monoclonal antibody complement inhibitor drug intended to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic
Dr. Rottinghaus was a senior director at Pfizer prior to joining Alexion, where he was responsible for advancing a number of therapeutic programmes, including tofacitinib in rheumatology and dermatology as well as tigecycline, voriconazole, and anidulafungin in the field of infectious diseases.
He participated in early-stage clinical studies for the development of an influenza vaccine as a clinician earlier in his Pfizer career.
Dr. Rottinghaus has experience serving on the FDA Advisory Committee and submitting numerous NDA and MAA filings.
Dr. Rottinghaus continued to work as an attending physician and assistant clinical professor of infectious diseases at Yale School of Medicine during his career in the industry.
More than 30 scientific publications that he co-authored.
Dr. Rottinghaus has a medical degree from Mayo Medical School, a master’s degree in science in biology from the University of Cambridge, where he was a Marshall Scholar, and a bachelor’s degree in biology and Latin and Greek from Kansas State University.
